Public annual accounts

DECURA PHAR financials

Name: DECURA PHAR financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for DECURA PHAR, with comparable measures and links to available source documents.

Company overview

Registry number

0833331354

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 28, 2026

Financial evidence

Latest movements for DECURA PHAR

2025 versus 2024

Operating line: €45,489
EBITDA: €44,077
Total assets: €1,411,421
Equity: €453,454

EBITDA margin +96.9% · Equity ratio +32.1%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202530 Jun 2025	€45,489	€44,077	€1,411,421	€453,454	-
202430 Jun 2024	€96,463	€94,640	€1,444,594	€438,546	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report